



SUBSCRIB **SIGN IN**

SUBSCRIBE

SIGN IN



SUBSCRIBE SIGN IN

Ivermectin Didn't Reduce Covid-19 Hospitalizations in Largest Trial to Date

Patients who got the antiparasitic drug didn't fare better than those who received a placebo



Amid a surge in cases, some countries are handing out second booster shots. In Israel, early data suggest a fourth vaccine dose can increase antibodies against Covid-19, but not enough to prevent infections from Omicron. WSJ explains. Photo composite: Eve Hartley/WSJ

By [Sarah Toy](#) [Follow](#)

Updated Mar. 18, 2022 10:16 am ET



SUBSCRIB SIGN IN

TO READ THE FULL STORY

SUBSCRIBE

SIGN IN

THE WALL STREET JOURNAL.

Continue reading your article with
a WSJ membership

VIEW MEMBERSHIP OPTIONS



SUBSCRIB



SUBSCRIBE SIGN IN

SPONSORED OFFERS

WAYFAIR: Extra 15% off + free shipping at Wayfair

TURBOTAX: Save up to an additional \$20 with TurboTax March 2022

H&R BLOCK TAX: Save up to \$40 with H&R Block compared to TurboTax

TARGET: Up to 60% off - Target Promo Code

SAMSUNG: 30% off smartphones + free shipping - Samsung promo code

AT&T: Get an extra \$50 Reward Card with AT&T Promo Code

BACK TO TOP ↗

THE WALL STREET JOURNAL. English Edition ▾ Edition

SUBSCRIBE NOW

SIGN IN

WSJ Membership

Customer: English

Is & Features

WSJ+ Membership Benefits

Customer Center

Newsletters & Alerts

Advertise

About Us



SUBSCRIBE SIGN IN

Corporate Subscriptions

Professor Journal

Student Journal

WSJ High School Program

Public Library Program

WSJ Live

WSJ Membership Benefits

Customer Center

Legal Policies

My News

RSS Feeds

Video Center

Watchlist

Podcasts

Visual Stories

Sell Your Business

Sell Your Home

Recruitment & Career Ads

Coupons

Digital Self Service

Corrections

Jobs at WSJ

News Archive

Register for Free

Reprints & Licensing

Buy Issues

WSJ Shop



Dow Jones Products

Barron's

BigCharts

Dow Jones Newswires

Factiva

Financial News

Mansion Global

MarketWatch

Private Markets

Risk & Compliance

WSJ Pro

WSJ Video

WSJ Wine

Privacy Notice

Cookie Notice

Copyright Policy

Data Policy

Subscriber Agreement & Terms of Use

Your Ad Choices

Accessibility

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved.

BACK TO TOP

English Edition
Edition

English



SUBSCRIBE **SIGN IN**

WSJ Membership	Customer Service	Tools & Features	Ads	More
WSJ+ Membership Benefits	Customer Center	Newsletters & Alerts	Advertise	About Us
Subscription Options	Contact Us	Guides	Commercial Real Estate Ads	Commercial Partnerships
Why Subscribe?		Topics	Place a Classified Ad	Content Partnerships
Corporate Subscriptions		My News	Sell Your Business	Corrections
Professor Journal		RSS Feeds	Sell Your Home	Jobs at WSJ
Student Journal		Video Center	Recruitment & Career Ads	News Archive
WSJ High School Program		Watchlist	Coupons	Register for Free
Public Library Program		Podcasts	Digital Self Service	Reprints & Licensing
WSJ Live		Visual Stories		Buy Issues
WSJ Membership Benefits				WSJ Shop
Customer Center				
Legal Policies				

SIGN IN

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved.